What it said it expected, against what it reported
No target with a reported result yet
The numbers SYK said it expected, in its earnings releases, next to what it then reported for the same period.
Target by target
Each target, with the sentence it came from
| Target | What the company said | Reported | Result |
|---|---|---|---|
| Diluted EPS (company-defined) Fiscal 2026 |
Given $14.90 to $15.10 release 2026-01-29
Kept $14.90 to $15.10 release 2026-04-30
Raised $14.95 to $15.10 release 2026-07-30
Lowered $14.80 to $14.90 release 2026-10-29
|
– | No standard number |
The company's wordsBased on our momentum exiting 2025, healthy procedural volumes and strong demand for our capital products, we expect 2026 organic net sales growth (2) to be in the range of 8.0% to 9.5% and adjusted net earnings per diluted share (2) to be in the range of $14.90 to $15.10. release 2026-01-29 We are maintaining our full year 2026 guidance of organic net sales growth (2) in the range of 8.0% to 9.5% and adjusted net earnings per diluted share (2) in the range of $14.90 to $15.10. release 2026-04-30 We are narrowing our full year 2026 guidance and now expect organic net sales growth (2) in the range of 8.3% to 9.3% and adjusted net earnings per diluted share (2) in the range of $14.95 to $15.10. release 2026-07-30 We are updating our full year 2026 guidance and now expect organic net sales growth (2) in the range of 6.5% to 7.0% and adjusted net earnings per diluted share (2) to be in the range of $14.80 to $14.90. release 2026-10-29 | |||
| Diluted EPS (company-defined) Fiscal 2025 (ended 2025-12-31) |
Given $13.45 to $13.70 release 2025-01-28
Lowered $13.40 to $13.60 release 2025-07-31
Raised $13.50 to $13.60 release 2025-10-30
|
– | No standard number |
The company's wordsBased on our momentum exiting 2024, a sustained level of procedural volumes, strong demand for our capital products and our presence in healthy end markets, we expect organic net sales growth (2) to be in the range of 8.0% to 9.0% for 2025 and expect adjusted net earnings per diluted share (2) to be in the range of $13.45 to $13.70. release 2025-01-28 Considering our year-to-date results, strong demand for our products and our operational momentum, we are raising our full year 2025 guidance and now expect organic net sales growth (2) of 9.5% to 10.0% and adjusted net earnings per diluted share (2) to be in the range of $13.40 to $13.60. release 2025-07-31 Based on our sales momentum, sustained demand for our products and commitment to margin expansion, we are raising our full year 2025 guidance and now expect organic net sales growth (2) of 9.8% to 10.2% and adjusted net earnings per diluted share (2) to be in the range of $13.50 to $13.60. release 2025-10-30 | |||
| Diluted EPS (company-defined) Fiscal 2024 (ended 2024-12-31) |
Given $11.70 to $12.00 release 2024-01-30
|
– | No standard number |
The company's wordsBased on our momentum from 2023, strong procedural volumes, healthy demand for capital products and a stabilizing macro-economic environment, we expect 2024 organic net sales growth (2) to be in the range of 7.5% to 9.0% and expect adjusted net earnings per diluted share (2) to be in the range of $11.70 to $12.00. release 2024-01-30 | |||
Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (13 releases since 2023-11-02), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.